The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
A common deletion polymorphism within B-cell chronic lymphocytic leukemia-lymphoma like 11 gene (BIM) was deemed to be a genetic cause leading to compromised kinase inhibitor therapeutic efficacy in cancer individuals. However, the results reported were not consistent. Thus, a comprehensive meta-analysis containing 12 eligible studies including 1,532 Asian patients was conducted to investigate a steady and reliable conclusion. The results showed that BIM deletion polymorphism was significantly associated with tyrosine kinase inhibitor (TKI) clinical efficacy in term of response rate (Ph = 0.349, HR = 0.438, 95%CI = 0.274–0.699) and disease control rate (Ph = 0.941, HR = 0.370, 95%CI = 0.202–0.678) in EGFR-mutated NSCLC population, not in CML and HCC subgroups. Additionally, EGFR-mutated NSCLC patient harbored BIM deletion polymorphism was associated with a shorter progression-free survival (PFS) than those with BIM wild polymorphism (Ph = 0.580, adjusted HR = 2.194, 95%CI = 1.710–2.814). However, no significant association was examined between BIM deletion polymorphism and overall survival (OS) and toxic adverse events in EGFR-mutated NSCLC population and it was not associated with PFS and OS in HCC subgroup. These findings revealed that BIM deletion polymorphism might be a genetic cause of intrinsic resistance to TKI therapy and it could be emerged as an independent predictor to identify patients who would benefit from TKI targeted therapy in EGFR-mutated NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The synonymous BIM polymorphism (rs724710) has a CC allele frequency that varies from 43–87% depending on the population background [28, 33, 40]”
From Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients (2024) · cites this paper as [40]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
The BCL-2 protein family: opposing activities that mediate cell death
Youle, R. J., & Strasser, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2308 · Cited by 4,679
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219
Comparison of two methods to detect publication bias in meta-analysis.
Peters, J. L. (2006) · JAMA · doi:10.1001/jama.295.6.676 · Cited by 2,278
Welch, V., Petticrew, M., Tugwell, P., Moher, D., O'Neill, J., Waters, E., White, H., & the PRISMA-Equity Bellagio group (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001333 · Cited by 704
Heterogeneity testing in meta‐analysis of genome searches
Zintzaras, E., & Ioannidis, J. P. A. (2005) · Genetic Epidemiology · doi:10.1002/gepi.20048 · Cited by 694
Bcl-2-family proteins: the role of the BH3 domain in apoptosis
Kelekar, A., & Thompson, C. B. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01321-x · Cited by 653
Ng, K. P., Hillmer, A. M., Chuah, C. T. H., Juan, W. C., Ko, T. K., Teo, A. S. M., Ariyaratne, P. N., Takahashi, N., Sawada, K., Fei, Y., et al. (2012) · Nature Medicine · doi:10.1038/nm.2713 · Cited by 557
Sos, M. L., Koker, M., Weir, B. A., Heynck, S., Rabinovsky, R., Zander, T., Seeger, J. M., Weiss, J., Fischer, F., Frommolt, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4055 · Cited by 504
Costa, D. B., Halmos, B., Kumar, A., Schumer, S. T., Huberman, M. S., Boggon, T. J., Tenen, D. G., & Kobayashi, S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040315 · Cited by 499
Keedy, V. L., Temin, S., Somerfield, M. R., Beasley, M. B., Johnson, D. H., McShane, L. M., Milton, D. T., Strawn, J. R., Wakelee, H. A., & Giaccone, G. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8923 · Cited by 486
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors
Faber, A. C., Corcoran, R. B., Ebi, H., Sequist, L. V., Waltman, B. A., Chung, E., Incio, J., Digumarthy, S. R., Pollack, S. F., Song, Y., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0106 · Cited by 283
EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.
Lin, Y., Wang, X., & Jin, H. (2014) · Europe PMC (PubMed Central) · Cited by 230
Terai, H., Soejima, K., Yasuda, H., Nakayama, S., Hamamoto, J., Arai, D., Ishioka, K., Ohgino, K., Ikemura, S., Sato, T., et al. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0652 · Cited by 206
FOXO3-induced reactive oxygen species are regulated by BCL2L11 (Bim) and SESN3
Hagenbuchner, J., Kuznetsov, A., Hermann, M., Hausott, B., Obexer, P., & Ausserlechner, M. J. (2012) · Journal of Cell Science · doi:10.1242/jcs.092098 · Cited by 187
BIM: Enabling Sustainability and Asset Management through Knowledge Management
Kivits, R. A., & Furneaux, C. W. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/983721 · Cited by 162
EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition
Nakagawa, T., Takeuchi, S., Yamada, T., Ebi, H., Sano, T., Nanjo, S., Ishikawa, D., Sato, M., Hasegawa, Y., Sekido, Y., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3479 · Cited by 157
Bim-targeted cancer therapy: A link between drug action and underlying molecular changes
Akiyama, T., Dass, C. R., & Choong, P. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0685 · Cited by 149
Hammerman, P. S., Jänne, P. A., & Johnson, B. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0189 · Cited by 145
Takezawa, K., Okamoto, I., Nishio, K., Jänne, P. A., & Nakagawa, K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2798 · Cited by 142
Lee, J. J.-K., Shin, J. Y., Kim, S., Lee, S., Park, C. C., Kim, J. Y., Koh, Y., Keam, B., Min, H. S., Kim, T. M., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt127 · Cited by 137 · cited 1×
“…positive CML 37 — — Imatinib ELN Retrospective Sustained CMR for > 24 months Fluctuating CMR for > 24 months Sustained or fluctuating CMR for > 24 months Lee 2013 Korea Asian Mutant EGFRNSCLC 193 37.10% IIIB-IV, relapse Gefitinib, erlotinib RESCIST 1.1 Retrospective CR/PR SD/PD RR, DCR,…”
BackgroundInfluentialImatinib and beyond—exploring the full potential of targeted therapy for CML
Quintás‐Cardama, A., Kantarjian, H. M., & Cortes, J. E. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.112 · Cited by 132 · cited 1×
“Ng 2012[2] Japan Asian Bcr-Abl1 positive CML 65 56.”
BackgroundHappo, L., Cragg, M. S., Phipson, B., Haga, J. M., Jansen, E. S., Herold, M. J., Dewson, G., Michalak, E. M., Vandenberg, C. J., Smyth, G. K., et al. (2010) · Blood · doi:10.1182/blood-2010-04-280818 · Cited by 107
Role of the BH3 (Bcl-2 homology 3) domain in the regulation of apoptosis and Bcl-2-related proteins
Lutz, R. J. (2000) · Biochemical Society Transactions · doi:10.1042/bst0280051 · Cited by 106
Pellicano, F., Scott, M. T., Helgason, G. V., Hopcroft, L. E. M., Allan, E. K., Aspinall-O’Dea, M., Copland, M., Pierce, A., Huntly, B. J. P., Whetton, A. D., et al. (2014) · Stem Cells · doi:10.1002/stem.1748 · Cited by 97
Zhao, M., Zhang, Y., Cai, W., Li, J., Zhou, F., Cheng, N., Ren, R., Zhao, C., Li, X., Ren, S., et al. (2014) · Cancer · doi:10.1002/cncr.28725 · Cited by 87 · cited 1×
“…events Lee 2014[1] Korea, Taiwan Asian Mutant EGFRNSCLC 146 39.20% IIIB-IV Gefitinib, erlotinib, afatinib RESCIST 1.1 Prospective CR/PR SD/PD RR, PFS, OS Zhao 2014 China Asian Mutant EGFRNSCLC 166 48.20% IIIB- IV Gefitinib, erlotinib RESCIST 1.1 Retrospective CR/PR SD/PD RR, DCR, PFS Table 1.”
InfluentialTargeted chronic myeloid leukemia therapy: Seeking a cure
Fausel, C. A. (2007) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070482 · Cited by 79
Takeda, M., Okamoto, I., Fujita, Y., Arao, T., Ito, H., Fukuoka, M., Nishio, K., & Nakagawa, K. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181cee47e · Cited by 76
Isobe, K., Hata, Y., Tochigi, N., Kaburaki, K., Kobayashi, H., Makino, T., Otsuka, H., Sato, F., Ishida, F., Kikuchi, N., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000125 · Cited by 71 · cited 1×
“…CR/PR SD/PD RR, DCR, PFS, adverse events Chen 2014 China Asian Bcr-Abl1 positive CML 220 50.90% — Imatinib ELN Retrospective Optimal response Suboptimal response or failure Sensitive, resistant Isobe 2014 Japan Asian Mutant EGFRNSCLC 70 27.10% IV, relapse Gefitinib, erlotinib RESCIST 1.1, CTC3.”
InfluentialSade, H., & Sarin, A. (2004) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401347 · Cited by 61
Rho, J. K., Choi, Y. J., Jeon, B.-S., Choi, S. J., Cheon, G. J., Woo, S., Kim, H.-R., Kim, C. H., Choi, C., & Lee, J. C. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0625 · Cited by 53
Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small-Cell Lung Cancer
Lee, J., Lin, Y., Hsu, W., Chen, H., Chang, Y., Yu, C., Shih, J., Lin, C., Chen, K., Ho, C., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000238 · Cited by 46
Nordigården, A., Kraft, M., Eliasson, P., Labi, V., Lam, E. W. ‐., Villunger, A., & Jönsson, J. (2008) · Blood · doi:10.1182/blood-2008-07-167023 · Cited by 41
Juan, W. C., Roca, X., & Ong, S. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095210 · Cited by 39
Shinohara, Y., Takahashi, N., Nishiwaki, K., Hino, M., Kashimura, M., Wakita, H., Hatano, Y., Hirasawa, A., Nakagawa, Y., Itoh, K., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.085167 · Cited by 31 · cited 4×
“0 Retrospective CR/PR SD/PD RR, DCR, PFS, adverse events Chen 2014 China Asian Bcr-Abl1 positive CML 220 50.90% — Imatinib ELN Retrospective Optimal response Suboptimal response or failure Sensitive, resistant Isobe 2014 Japan Asian Mutant EGFRNSCLC 70 27.10% IV, relapse Gefitinib, erlotinib RESCIST 1.1, CTC3.”
InfluentialSample size and statistical power in the small‐animal analgesia literature
Hofmeister, E. H., King, J., Read, M. R., & Budsberg, S. C. (2007) · Journal of Small Animal Practice · doi:10.1111/j.1748-5827.2006.00234.x · Cited by 30
Katagiri, S., Umezu, T., Ohyashiki, J. H., & Ohyashiki, K. (2012) · British Journal of Haematology · doi:10.1111/bjh.12111 · Cited by 19
Takeuchi, S., & Yano, S. (2014) · Respiratory Investigation · doi:10.1016/j.resinv.2014.10.002 · Cited by 18
Chen, X., Liu, H., Xing, H., Sun, H., & Zhu, P. (2014) · Nature Medicine · doi:10.1038/nm.3638 · Cited by 15
Self-citationZheng, L., Lin, B., Song, Z., Xie, F., Hong, W., Feng, J., Shao, L., & Zhang, Y. (2013) · PubMed Central · doi:10.3779/j.issn.1009-3419.2013.12.03 · Cited by 10
Ong, S. T., Chuah, C. T. H., Ko, T. K., Hillmer, A. M., & Lim, W. (2014) · Nature Medicine · doi:10.1038/nm.3652 · Cited by 9
Shao, Y., Chang, Y.-L., Huang, C.-Y., Hsu, C., & Cheng, A. (2013) · Oncology · doi:10.1159/000356019 · Cited by 7
The role of BIM-EL and BCL2-α on the efficacy of erlotinib and gefitinib in lung cancer
Simasi, J., Oelkrug, C., Schubert, A., Nieber, K., & Gillissen, A. (2014) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2014.09.022 · Cited by 6
The Potential Benefits of BIM in the Further Pursuit of Biomarker Discovery in Cancer Therapeutics
Yoshida, T., & Haura, E. B. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0193 · Cited by 6
A novel BIM deletion polymorphism: implications and lessons for cancer targeted therapies.
Soh, S. X., & Ong, S. T. (2013) · PubMed · Cited by 6
A novel BIM deletion polymorphism: implications and lessons for cancer targeted therapies.
Soh, S. X., & Ong, S. T. (2013) · PubMed · Cited by 6
Cited by
Regulation of Bim in Health and Disease
Sionov, R. V., Vlahopoulos, S. A., & Granot, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.5492 · Cited by 216
“Bim deletion polymorphism was significantly associated with the clinical efficacy of tyrosine kinase inhibitors in terms of response rate and disease control rate in EGFR-mutated NSCLC patients, but not in CML or hepatocellular carcinoma (HCC) [639].”
BackgroundGuo, Y., Song, J., Wang, Y., Huang, L., Sun, L., Zhao, J., Zhang, S., Jing, W., Ma, J., & Han, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.610923 · Cited by 95
Takeuchi, S., Hase, T., Shimizu, S., Ando, M., Hata, A., Murakami, H., Kawakami, T., Nagase, K., Yoshimura, K., Fujiwara, T., et al. (2019) · Cancer Science · doi:10.1111/cas.14260 · Cited by 40
“Median (range) 58 (8-574) 274 (8-518) 11 (8-191) 58 (14-574)”
The pharmacogenomics of drug resistance to protein kinase inhibitors
Gillis, N., & McLeod, H. L. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.06.008 · Cited by 33
“Nilotinib, the BCR-ABL PKI used in chemoresistant CML, also has activity against KIT, PDGFR, DDR, and several other protein kinases, with greater potency than imatinib.”
BackgroundInfluentialChallenges and Opportunities With Oncology Drug Development in China
Bajaj, G., Gupta, M., Wang, H. H., Barrett, J. S., Tan, M., Rupalla, K., Bertz, R., & Sheng, J. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1017 · Cited by 27
“In addition, 12% of East Asians harbor a germline deletion polymorphism in the BIM gene, which is associated with TKI resistance and poorer outcomes in patients with NSCLC; this mutation is absent from European and African populations.(15,16) An extrinsic ethnic factor of particular importance in China is the use of h…”
Background
Metadata
- Authors
- Ying, H.-Q., Chen, J., He, B.-S., Pan, Y.-Q., Wang, F., Deng, Q.-W., Sun, H.-L., Liu, X., & Wang, S.-K.
- Affiliations
- Nanjing First Hospital (CN)
- Nanjing Normal University (CN)
- Venue
- Scientific Reports
- Published
- 2015-06-15
- Volume
- 5
- Issue
- 1
- Pages
- 11348-11348
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC4466895
- OpenAlex
- W2399332576
- Cited by
- 29
- References
- 49
- Citations by year
- 2026: 3 · 2024: 2 · 2022: 2 · 2021: 1 · 2020: 3 · 2019: 4 · 2018: 4 · 2017: 6 · 2016: 2 · 2015: 2
- FWCI
- 0.83
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81172141)
- Nanjing Medical Science and Technique Development Foundation (QRX11254, QRX11255)
- Fundamental Research Funds for the Central Universities
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- BIM deletion polymorphism, BCL2L13, tyrosine kinase inhibitors, intrinsic drug resistance, EGFR-mutant non-small cell lung cancer, hepatocellular carcinoma, chronic myeloid leukemia, progression-free survival, predictive biomarkers, pharmacogenetics, targeted therapy
- MeSH terms
- Bcl-2-Like Protein 11, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Humans, Membrane Proteins, Neoplasms, Polymorphism, Genetic, Proto-Oncogene Proteins, Signal Transduction, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Gene Expression Regulation, Neoplastic, Survival Analysis, Treatment Outcome, Sequence Deletion, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Apoptosis Regulatory Proteins, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.